#SARS-CoV-2 infection rate low in patients receiving antitumor therapy

“#SARS-CoV-2 infection rate low in patients receiving antitumor therapy”

(HealthDay)—The rate of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection is 0.68 percent among patients receiving antitumor treatment, according to a research letter published online Dec. 17 in JAMA Oncology.

Carlo Aschele, M.D., Ph.D., from Ospedale Sant’Andrea in La Spezia, Italy, and colleagues calculated the rate of SARS-CoV-2 infection among patients receiving antitumor treatment at 118 medical oncology units affiliated with the Collegio Italiano dei Primari Oncologi Medici Ospedalieri in Italy. Data were included for 59,989 patients receiving antitumor treatment between Jan. 15 and May 4, 2020.

The researchers found that 406 of the patients (0.68 percent) developed COVID-19 and had a positive nasopharyngeal polymerase chain reaction test result. Most infected patients (83 percent) were symptomatic and 77 percent required hospitalization. The most common tumor was lung cancer (22 percent) and the most represented antitumor treatment was chemotherapy (62 percent). Compared with the general Italian population during the same time period, the infection rate was higher and varied between different geographical areas.

“From a clinical point of view, the low probability of SARS-CoV-2 infection among these patients (

One author disclosed financial ties to the pharmaceutical industry.

Increased risk for SARS-CoV-2 seen in cancer patients in Wuhan

More information:
Abstract/Full Text

Citation:
SARS-CoV-2 infection rate low in patients receiving antitumor therapy (2020, December 28)
retrieved 28 December 2020
from https://medicalxpress.com/news/2020-12-sars-cov-infection-patients-antitumor-therapy.html

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no
part may be reproduced without the written permission. The content is provided for information purposes only.

If you liked the article, do not forget to share it with your friends. Follow us on Google News too, click on the star and choose us from your favorites.